Atea Pharmaceuticals announced its first-quarter 2026 financial results, reporting a net loss of $45.4 million, or $0.57 per share, which beat analyst expectations of $0.59 per share loss. The company ended the quarter with $256.0 million in cash, cash equivalents, and marketable securities, providing a runway into 2027.4445
Financial Highlights
Research and development expenses rose to $41.1 million from $29.6 million in the prior-year quarter, reflecting increased external spending on Phase 3 hepatitis C virus (HCV) trials and hepatitis E virus (HEV) preclinical work.44 General and administrative costs fell to $6.9 million from $9.5 million, driven by lower salaries, stock-based compensation, and professional fees. Interest income dropped to $2.6 million from $5.0 million.44
HCV Program Advances
Enrollment completed in the North American Phase 3 C-BEYOND trial with over 880 patients; topline data expected mid-2026. The international C-FORWARD trial remains on track for enrollment completion mid-2026, with results anticipated by year-end.4445
The regimen pairs bemnifosbuvir, a nucleotide analog polymerase inhibitor, with ruzasvir, an NS5A inhibitor, for once-daily oral dosing over 8 weeks without cirrhosis or 12 weeks with compensated cirrhosis. Phase 2 data showed 98% SVR12 rates in the per-protocol population.44
Potential Profile
Officials highlight high efficacy, short duration, low drug-drug interactions—even with proton pump inhibitors and statins—and no food restrictions or dose adjustments for liver or kidney impairment.45
HEV Program Update
Atea selected AT-587 as the lead candidate for chronic HEV in immunocompromised patients, where no approved therapies exist. Preclinical data demonstrate superior potency over standard treatments. A Phase 1 trial in healthy volunteers starts mid-2026, followed by proof-of-concept studies by year-end.4445
Executive Commentary
“With two pivotal Phase 3 readouts for our HCV program on the horizon, 2026 will be a catalyst-rich year for Atea,” stated Jean-Pierre Sommadossi, Founder, Chairman, CEO, and President. “The data generated to date for the regimen of bemnifosbuvir and ruzasvir support a differentiated, potentially best-in-class profile… an opportunity to accelerate HCV elimination efforts.”44
Sommadossi added on the HEV effort: “HEV represents a critical gap in care… we look forward to advancing our potential first-in-class candidate, AT-587, into the clinic mid-year.”44
Outlook
Analysis indicates 2026 focuses on HCV Phase 3 milestones and HEV initiation, amid ongoing clinical and regulatory risks. Additional data presentations occur at upcoming conferences like EASL.45
